文献速递神经肿瘤

赖氨酸特异性去甲基化酶1的药理学抑制作为儿童高级别胶质瘤的治疗和免疫增敏策略

Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma.
PubMed 文献 · Neuro Oncol · 2020-01-01

本研究利用患者来源的弥漫性内生型脑桥胶质瘤(DIPG)细胞系、原位小鼠模型和儿童高级别胶质瘤(pHGG)数据集,评估赖氨酸特异性去甲基化酶1(LSD1)抑制剂对细胞毒性和免疫基因表达的影响。结果显示,催化型LSD1抑制剂在DIPG中具有选择性细胞毒性,可诱导免疫基因特征并增强自然杀伤(NK)细胞杀伤作用,而支架型LSD1抑制剂对NK细胞有毒且不诱导该基因特征。

要点

  • 催化型LSD1抑制剂在DIPG中具有选择性细胞毒性,并在体内作为单药显示疗效。
  • LSD1调控的基因特征可预测pHGG患者生存,并在LSD1抑制剂治疗小鼠的神经组织中可见。
  • LSD1抑制在体内和体外增强NK细胞对DIPG的细胞毒性,并伴有相关遗传生物标志物。

核心结论

  • 使用催化型抑制剂的LSD1抑制具有选择性细胞毒性,并促进免疫基因特征,在体外和体内增加NK细胞杀伤,代表pHGG的治疗机会。

研究设计与样本

  • 使用患者来源的DIPG细胞系、原位小鼠模型和pHGG数据集评估LSD1抑制剂对细胞毒性和免疫基因表达的影响。

主要发现

  • 在DIPG细胞系中,临床相关LSD1抑制剂确立了选择性细胞毒性和免疫原性基因特征。
  • pHGG患者测序数据证明该LSD1依赖基因特征具有生存获益。
  • 用这些抑制剂预处理DIPG可增加自然杀伤(NK)细胞的裂解作用。
  • 催化型LSD1抑制剂在体内诱导肿瘤消退并增强NK细胞输注以减少肿瘤负荷。
  • 对患者数据的CIBERSORT分析证实NK细胞浸润有益于患者生存,而CD8 T细胞为负预后因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diffuse midline gliomas (DMG), including brainstem diffuse intrinsic pontine glioma (DIPG), are incurable pediatric high-grade gliomas (pHGG). Mutations in the H3 histone tail (H3.1/3.3-K27M) are a feature of DIPG, rendering them therapeutically sensitive to small-molecule inhibition of chromatin modifiers. Pharmacological inhibition of lysine-specific demethylase 1 (LSD1) is clinically relevant but has not been carefully investigated in pHGG or DIPG. METHODS: Patient-derived DIPG cell lines, orthotopic mouse models, and pHGG datasets were used to evaluate effects of LSD1 inhibitors on cytotoxicity and immune gene expression. Immune cell cytotoxicity was assessed in DIPG cells pretreated with LSD1 inhibitors, and informatics platforms were used to determine immune infiltration of pHGG. RESULTS: Selective cytotoxicity and an immunogenic gene signature were established in DIPG cell lines using clinically relevant LSD1 inhibitors. Pediatric HGG patient sequencing data demonstrated survival benefit of this LSD1-dependent gene signature. Pretreatment of DIPG with these inhibitors increased lysis by natural killer (NK) cells. Catalytic LSD1 inhibitors induced tumor regression and augmented NK cell infusion in vivo to reduce tumor burden. CIBERSORT analysis of patient data confirmed NK infiltration is beneficial to patient survival, while CD8 T cells are negatively prognostic. Catalytic LSD1 inhibitors are nonperturbing to NK cells, while scaffolding LSD1 inhibitors are toxic to NK cells and do not induce the gene signature in DIPG cells. CONCLUSIONS: LSD1 inhibition using catalytic inhibitors is selectively cytotoxic and promotes an immune gene signature that increases NK cell killing in vitro and in vivo, representing a therapeutic opportunity for pHGG. KEY POINTS: 1. LSD1 inhibition using several clinically relevant compounds is selectively cytotoxic in DIPG and shows in vivo efficacy as a single agent.2. An LSD1-controlled gene signature predicts survival in pHGG patients and is seen in neural tissue from LSD1 inhibitor-treated mice.3. LSD1 inhibition enhances NK cell cytotoxicity against DIPG in vivo and in vitro with correlative genetic biomarkers.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Bailey CP, Figueroa M, Gangadharan A, et al. Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma. Neuro Oncol. 2020. PMID: 32166329. doi:10.1093/neuonc/noaa058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。